Bibliography: leaves 123-141. / xv, 141 leaves : ill. (some col.) ; 30 cm. / Title page, contents and abstract only. The complete thesis in print form is available from the University Library. / This thesis developes specific tools to monitor receptor expression in a ligand-independent manner, demonstrates the receptor expression is not static and can be modulated by cytokines, identifies strong evidence in defining the N-terminal domain of IL-3R & chain and B'C' and F'G' loopes of domain 4 of Bc as functional domains involved in ligand binding and function and provides novel potential therapeutics. / Thesis (Ph.D.)--University of Adelaide, Dept. of Medicine, 1997

Thesis (Ph. D.)--West Virginia University, 2007. / Title from document title page. Document formatted into pages; contains xii, 156 p. : ill. (some col.). Vita. Includes abstract. Includes bibliographical references.

Thesis (Ph. D.)--University of Hong Kong, 2009. / Includes bibliographical references (leaves 131-149). Also available in print.

Thesis (doctoral)--Lund University, 1997. / Added t.p. with thesis statement inserted.

Thesis (doctoral)--Lund University, 1992. / Added t.p. with thesis statement inserted.

Thesis (doctoral)--Lund University, 1992. / Added t.p. with thesis statement inserted.

Thesis (doctoral)--Lund University, 1997. / Added t.p. with thesis statement inserted.

The colony-stimulating factor-1 receptor (CSF-1R) is expressed by the mononuclear phagocytic lineage, and is important for the development of these cells from their progenitors and also for promoting their survival and activation after maturation. The receptor has two ligands, CSF-1 and IL-34, which induce the formation of a stable dimer between two receptor monomers. This leads to intracellular autophosphorylation of tyrosine residues and subsequent signalling cascades, leading to rapid protein expression, cytoskeleton remodelling and cellular motility. Although CSF-1R signalling is crucial for normal embryogenic development and other physiological functions mediated by the phagocytic lineage, it has also been found to promote the pathogenic progression of cancer. Tumour-associated macrophages (TAMs) can comprise a large proportion of the cellular population in several solid tumours. These cells promote several hallmarks of cancer malignancy, such as increased neovascularization, tissue invasion, induction of metastases and immunosuppression. In this work, it was confirmed that CSF-1 had a prominent role in inducing cancer-promoting cellular phenotypes. Both canine cancer cells and macrophages respond to this cytokine, respectively increasing cancer cell proliferation and reducing inflammatory activation. Given the importance of CSF-1R signalling in the tumour microenvironment, antibodies were generated with the objective of blocking receptor function. Mice were immunized with either the extracellular region or the dimerization domain of the CSF-1R. Hybridomas were produced using the primed splenocytes, and monoclonal antibody (mAb) candidates were selected based on their performance in immunostaining and on their capacity to inhibit CSF-1R+ cells. The best antibodies were subjected to speciation. Chimeric antibodies maintained the ability of the parental mAbs to inhibit macrophage proliferation following CSF-1R stimulation. However, the mAbs possessed moderate affinity and specificity for their target, failing to stain monocytes and presenting a degree of cross-reactivity. The binding properties of one of such mAbs were altered by PCR-induced mutations, generating semi-synthetic antibody libraries. These were screened by phage display, yielding novel clones that show reduced cross-reactivity with unrelated proteins and retain the property of inhibiting macrophage survival. These results are a step in the development of therapeutic monoclonal antibodies for cancer treatment in dogs.

No description available.

Made available in DSpace on 2014-06-11T19:23:07Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-02-24Bitstream added on 2014-06-13T19:29:04Z : No. of bitstreams: 1 guilherme_grb_me_botfm.pdf: 2588332 bytes, checksum: 8ef4f30634a7a7abfb353bf08791a95c (MD5) / Fundação para o Desenvolvimento Médico e Hospitalar (Famesp) / Secretaria do Estado da Saúde de São Paulo / O sistema imunológico é dividido em imunidade natural e adquirido (humoral e celular). Os linfócitos B são os principais efetores da resposta humoral. Junto aos linfócitos T, mediam diversas reações imunológicas. Todos os leucócitos possuem antígenos de superfície (clusters of differentiation – CD) determinados que possuem as mais diferentes funções. As expressões destes CDs podem variar na maturação e na presença de patologias, sendo as de maior prevalência e gravidade as leucemias e linfomas, tornando-se marcadores importantes que podem ser avaliados por citometria de fluxo ou imunoquímica através do uso de anticorpos monoclonais murinos (AcMm). Após produção dos AcMm é necessário caracterizar e validá-los. Utilizou-se 11 clones que apresentaram especificidade somente contra linfócitos B. Pela técnica de Western Blotting, 5 anticorpos (3 do tipo IgM e 2 do tipo IgG) foram escolhidos de acordo com sua possível especificidade e importância clínica. A validação dos anticorpos tipo IgM foi realizada por citometria de fluxo utilizando anticorpo comercial para comparação de quantidade de células marcadas, sendo testados em 20 amostras de indivíduos normais e 20 de indivíduos portadores de neoplasias hematológicas diversas. O LINB B, que foi comparado com o anti-CD171 e anti-CD45RA, apresentando diferença estatística somente em relação ao anti-CD45RA, e identidade com o anti-CD171. O LINB C, que foi comparado com o anti-CD20 e anti-CD19, não apresentou diferença estatística significante quando frente a ambos anticorpos comerciais. No teste de regressão linear, houve maior correlação dos resultados com o anti-CD19. O LINB E foi comparado somente contra o anti-CD107b, havendo grande identidade entre os dois. Dos resultados apresentados, conclui-se que o LINBs B e E apresentam grandes chances de serem específicos contra... / The immunological system is divided into: natural immunity and acquired immunity (celular and humoral responses). The B lymphocytes are the main effectors of the humoral response. Together with the T lymphocytes, they make several immunological reactions. All leucocytes have antigens on the surface (clusters of differentiation – CD) that possess lot of functions. The expressions of these CDs may be altered during maturation and pathologies, like leukemia and lymphomas, becoming important markers that can be evaluated by flow cytometry or immunochemistry thought murine monoclonals antibodies (Mab). After production of Mabs it´s necessary characterize and validated them. We used 11 clones that presented Mab against B lymphocytes only. By Western Blotting method 5 Mab (3 IgM and 2 IgG) were chosen according you possible especifity and clinical importance. The validation of IgM Mabs were made by flow cytometry using commercial antibody to compare the quantity of marked cells, being used 20 samples from normal people and 20 samples from person with hematological cancer. The LINB B, compared to anti-CD171 and anti-CD45RA, presented statistical difference from anti-CD45RA and identity to anti-CD171. The LINB C, compared to anti-CD19 and anti-CD20, didn´t presented any statistical difference from both commercial antibodies, although it correlates better with anti-CD19. The LINB E was compared to anti-CD107b, where it appears great identity between then. By the present results, we conclude that LINB B and E need multicentre studies to expand validation, and LINB C, needs to increase the samples to have a statistical validation. The two IgGs LINB, possible anti-CD138, weren´t test yet.